UNSPSC 51312403: Tripelennamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H21N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C5ORO99TY, chemically known as 1,2-ethanediamine, n, n-dimethyl-n- (phenylmethyl)-n-2-pyridinyl-, monohydrochloride but generally known as tripelennamine, which bears US NIH Compound Identifier 5587. European Medicines Agency schedules Tripelennamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11322MIG.

UNSPSC 51312403 Tripelennamine is a Commodity code that classifies pharmaceutical products, yet recent state and local solicitations under this code show a much broader scope than the code's narrow product name suggests — jurisdictions are actually purchasing naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment systems. State and local issuers include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida procures naloxone and drug deactivation systems for community health initiatives; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, solicits generic pharmaceuticals and OTC products on behalf of participating state and local government facilities across multiple states including Oregon. The scope spans both product procurement and program-design services, with recent activity mixing commodity purchases against exploratory market-intelligence vehicles and multistate cooperative frameworks.

Geographic activity clusters in the South and Midwest. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) sought 1,900 units annually with quarterly delivery to Sanford, Florida; the Texas HHS Commission's RFI (HHS0017013, response due April 3, 2026) targeted direct-to-manufacturer capability assessment; and MMCAP's RFP for generic pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) spans Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson). The MMCAP procurement uses weighted evaluation criteria emphasizing price competitiveness at 75 percent, with lesser weight on compliance and administrative capability, and imposes performance penalties of $200 to $1,500 per violation. Neither Seminole County nor MMCAP specified set-aside designations in their published materials, though both require E-Verify compliance and standard insurance coverage.